Article Text

  1. K. E. Jackson1,
  2. W. Durante1,
  3. K. J. Peyton1,
  4. R. A. Johnson1,
  5. F. K. Johnson1
  1. 1Department of Physiology, Tulane University Health Sciences Center, New Orleans


The release of nitric oxide (NO) through the oxidation of L-arginine by endothelial NO synthase (eNOS) promotes relaxation of vascular smooth muscle and plays a pivotal role in the maintenance of vascular homeostasis. Since L-arginine is an exclusive substrate for eNOS, its availability can regulate NO formation. Endothelial dysfunction, due to decreased NO function, is a prominent feature of obesity and type 2 diabetes and contributes to cardiovascular pathology. While eNOS expression is unchanged, vascular NO levels are decreased and L-arginine administration lowers blood pressure in patients with type 2 diabetes. This study tests the hypothesis that L-arginine restores coronary arterial endothelial function in obese Zucker rats (ZR), experimental models of type 2 diabetes. Male obese ZR (548 ± 12 g) and lean Sprague-Dawley (SD) rats (300 g) were used for the study. Mean arterial blood pressure (154 ± 3 mm Hg) and fasting blood glucose levels (186 ± 7 mg/dL) were elevated in obese ZR. Experiments were performed on isolated pressurized (80 mm Hg no flow conditions) small septal coronary arteries (200-300 μm) superfused with oxygenated (14% O2, 5% CO2 balanced with N2) Krebs buffer. Responses to an endothelium- and NO-dependent vasodilator, acetylcholine (1 nmol/L-3 μmol/L) were greatly attenuated in obese ZR coronary vessels (Δmax 5 ± 2 μm vs. 54 ± 10 μm). Acute in vitro pretreatment with the NOS substrate, 1 mmol/L L-arginine, enhanced acetylcholine-induced dilation and abolished the differences between obese ZR and SD arteries (Δmax 48 ± 18 μm vs. 61 ± 18 μm). These data show that blood pressure and blood glucose levels are elevated in obese ZR. Acetylcholine-induced endothelium-dependent vasodilation is greatly attenuated in small coronary arteries isolated from obese ZR. In addition, acute in vitro administration of L-arginine enhanced coronary endothelium-dependent responses and abolished the differences between obese ZR and SD coronary vessels. These results suggest that decreased L-arginine availability may contribute to coronary arterial endothelial dysfunction in obese ZR. Thus, L-arginine supplementation may present a novel therapeutic method to deter coronary vascular endothelial dysfunction and cardiovascular complications in patients with obesity and type 2 diabetes.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.